Trials / Terminated
TerminatedNCT01167816
Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- University of Oklahoma · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to determine the maximum tolerated dose (MTD) of azacitidine and gemcitabine in subjects with previously untreated and unresectable pancreatic cancer. Also to determine the effect of azacitidine therapy on DNA methylation in peripheral blood cells.
Detailed description
This is a Phase I single arm study designed for subjects with newly diagnosed, unresectable pancreatic cancer who have received no prior chemotherapy, radiation therapy, or surgery with curative intent for pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vidaza | Vidaza will be administered subq daily for 5 consecutive days each 28-day cycle |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2014-01-01
- Completion
- 2014-01-01
- First posted
- 2010-07-22
- Last updated
- 2014-05-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01167816. Inclusion in this directory is not an endorsement.